On December 20th, 2019, a magistrate judge recommended in a preliminary report that 2 out of the 4 claims in CareDx's false advertising suit against Natera be dismissed. The magistrate's recommendation is based on the sufficiency of the pleadings, rather than on the merits of any claim. We are pleased with this outcome and we look forward to prevailing on any remaining claims, should the case make it to trial.
Despite CareDx's repeated attempts to discredit the performance capabilities of the Prospera test --- which has been clinically and analytically validated by scientific, peer-reviewed evidence --- we believe that we will prevail in this suit and that CareDx's meritless claims against Natera will not disrupt the launch of Prospera and our mission to support improved patient care.
Attachments
Original document
Permalink
Disclaimer
Natera Inc. published this content on 09 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 January 2020 19:22:07 UTC
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of womenâs health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Companyâs algorithms and bioinformatics in order to validate and launch tests based on the Companyâs technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
NATERA, INC. 
